GSK Drug Bepirovirsen Shows Promise in Redefining Chronic Hepatitis B Treatment
British pharmaceutical company GSK has reported encouraging late-stage clinical trial results for bepirovirsen, an investigational therapy for chronic hepatitis B (CHB), raising hopes for a potential shift away from lifelong treatment toward finite therapy with significantly higher functional cure rates. The findings, presented at the European Association for the Study of the Liver (EASL) Congress and simultaneously published in the New England Journal of Medicine, suggest the drug could mark a major advance in a disease that affects more than 240 million people globally.
According to GSK, bepirovirsen achieved a functional cure rate of 19% in the overall study population enrolled in the pivotal Phase III B-Well 1 and B-Well 2 trials. In a subgroup of patients with lower viral activity, functional cure rates increased to 26%, compared with no functional cures in patients receiving standard treatment alone. Functional cure in chronic hepatitis B refers to the sustained disappearance of detectable hepatitis B virus DNA and surface antigen after treatment has stopped, allowing immune control of the disease without ongoing medication.
The two studies evaluated bepirovirsen, an antisense oligonucleotide therapy designed to reduce hepatitis B viral proteins and help restore the body’s immune response against infection. Patients received six months of treatment alongside the current standard of care, which typically involves long-term antiviral medicines. Existing therapies rarely achieve functional cure, with rates generally below 1% to 4%, meaning most patients require lifelong management to suppress the virus and reduce complications.
GSK also reported that 49% of participants receiving bepirovirsen achieved hepatitis B surface antigen levels of 100 IU/mL or lower one year after treatment in an exploratory analysis, a finding considered clinically important because lower antigen levels are associated with reduced risks of liver-related complications, including liver cancer. Chronic hepatitis B remains one of the leading causes of liver cancer worldwide, underscoring the need for more effective therapies.
The promising results strengthen GSK’s regulatory push for bepirovirsen, which has already been submitted for review in several major markets, including the United States, Europe, Japan and China. Industry analysts view the drug as a potentially important commercial and clinical asset for GSK, particularly as the company expands its infectious disease portfolio. If approved, bepirovirsen could offer patients a time-limited treatment option capable of delivering durable disease control rather than indefinite viral suppression.